Patrick Y. Wen
Expertise in
26
conditions

Dr. Patrick Y. Wen

Neurology
450 Brookline Avenue, 
Boston, MA 
Offers Telehealth
Expertise in
26
conditions
450 Brookline Avenue, 
Boston, MA 

Overview

Patrick Wen is a Neurologist in Boston, Massachusetts. Dr. Wen is highly rated in 26 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

His clinical research consists of co-authoring 564 peer reviewed articles and participating in 35 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of London, 1981

Residency

Whittington/Royal Northern Hospital, London, 1982 - 1983

Specialties

Neurology

Licenses

Psychiatry & Neurology in MA

Board Certifications

Neurology
Neuro-Oncology

Hospital Affiliations

Brigham And Women's Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute, Center for Neuro-Oncology
450 Brookline Avenue, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

35 Clinical Trials

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
Enrollment Status: Completed
Publish Date: November 03, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas
A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Drug, Other
Study Drugs: Temozolomide, Vorinostat
Study Phase: Phase 1
A Phase 2 Study of Abemaciclib and Pembrolizumab in Recurrent Glioblastoma
A Phase 2 Study of Abemaciclib and Pembrolizumab in Recurrent Glioblastoma
Enrollment Status: Withdrawn
Publish Date: August 11, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients With Surgically Accessible Glioblastoma
A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients With Surgically Accessible Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Drug, Procedure
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 1
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients
Enrollment Status: Completed
Publish Date: July 11, 2025
Intervention Type: Biological, Drug
Study Drug: Oncolytic Polio/Rhinovirus Recombinant Vaccine
Study Phase: Phase 2
A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Enrollment Status: Terminated
Publish Date: June 10, 2025
Intervention Type: Other, Drug, Procedure
Study Drugs: Ofranergene Obadenovec, Bevacizumab
Study Phase: Phase 2
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Biological
Study Drugs: PVSRIPO, Pembrolizumab
Study Phase: Phase 2
Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drugs: MN-166, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
Enrollment Status: Completed
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drug: Paxalisib (GDC-0084)
Study Phase: Phase 2
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: MK-3475
Study Phase: Phase 1
A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug
Study Phase: Not Applicable
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Radiation, Biological, Other, Drug
Study Drugs: AdV-tk, Valacyclovir, Temozolomide, Nivolumab
Study Phase: Phase 1
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Procedure
Study Drugs: BGB-290 PARP Inhibitor, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Enrollment Status: Terminated
Publish Date: October 31, 2024
Intervention Type: Biological, Drug
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: June 24, 2024
Intervention Type: Drug, Radiation
Study Drug: BAL101553
Study Phase: Phase 1
Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Bavituximab
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2024
Intervention Type: Biological
Study Drug: SurVaxM
Study Phase: Phase 2
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drugs: Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Anti-CD137
Study Phase: Phase 1
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Drug
Study Drug: Regadenoson
Study Phase: Phase 1
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Other, Drug
Study Drug: Terameprocol
Study Phase: Phase 1
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drug: NT-I7
Study Phase: Phase 1
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
Enrollment Status: Terminated
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Biological, Other, Drug
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 1
A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation
A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation
Enrollment Status: Unknown
Publish Date: October 18, 2022
Intervention Type: Drug
Study Drug: AZD2014
Study Phase: Phase 2
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 2
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
Enrollment Status: Completed
Publish Date: April 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase I Trial of Pomalidomide for Patients With Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma
Phase I Trial of Pomalidomide for Patients With Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma
Enrollment Status: Completed
Publish Date: July 22, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Phase I Study of Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor
A Phase I Study of Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor
Enrollment Status: Completed
Publish Date: June 22, 2017
Intervention Type: Biological
Study Phase: Phase 1
Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma
Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma
Enrollment Status: Completed
Publish Date: May 15, 2017
Intervention Type: Drug, Other
Study Phase: Phase 2
View 34 Less Clinical Trials

563 Total Publications

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
Similar Doctors
Expertise in
38
conditions
Dr. Scott Plotkin
Neurology
Expertise in
38
conditions
Dr. Scott Plotkin
Neurology

Office

55 Fruit St # 9, 
Boston, MA 
 (2.7 miles away)
617-724-8770
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Plotkin is a Neurologist in Boston, Massachusetts. Dr. Plotkin is highly rated in 38 conditions, according to our data. His top areas of expertise are Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis, and Acoustic Neuroma.

Expertise in
53
conditions
Dr. Annapurna Poduri
Neurology
Expertise in
53
conditions
Dr. Annapurna Poduri
Neurology

Boston Children's Hospital

300 Longwood Ave, 
Boston, MA 
 (0.1 miles away)
617-730-7970
Languages Spoken:
English
See accepted insurances

Annapurna Poduri is a Neurologist in Boston, Massachusetts. Dr. Poduri is highly rated in 53 conditions, according to our data. Her top areas of expertise are West Syndrome, Epilepsy, Spasmus Nutans, and Cortical Dysplasia.

Expertise in
76
conditions
Dr. Jeremy Schmahmann
Neurology
Expertise in
76
conditions
Dr. Jeremy Schmahmann
Neurology

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-726-3216
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Schmahmann is a Neurologist in Boston, Massachusetts. Dr. Schmahmann is highly rated in 76 conditions, according to our data. His top areas of expertise are Spinocerebellar Ataxia, Acute Cerebellar Ataxia, Olivopontocerebellar Atrophy, Drug Induced Dyskinesia, and Gastrostomy.

Frequently Asked Questions about Dr. Patrick Y. Wen

How do I make an appointment with Dr. Patrick Y. Wen?

You can book an appointment with Dr. Patrick Y. Wen by calling their office at 617-632-2166. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Patrick Y. Wen a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Patrick Y. Wen is classified as an Elite expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Patrick Y. Wen specialize in?

While Dr. Patrick Y. Wen is a Neurology, they have specific expertise in Glioblastoma, Astrocytoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Patrick Y. Wen participate in research or clinical trials?

Yes. Dr. Patrick Y. Wen has published 563 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. Patrick Y. Wen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Patrick Y. Wen accept my insurance?

Dr. Patrick Y. Wen accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-632-2166 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wen's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 8 Distinguished Conditions
View All 9 Advanced Conditions
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile